1. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs); 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf . Accessed 19 Dec 2013.
2. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Draft; 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf . Accessed 17 Feb 2014.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Inflectra (infliximab); 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf . Accessed 17 Feb 2014.
4. Siddiqui MAA, Scott LJ. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. Drugs. 2005;65:2179–208.
5. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs. 2002;16(2):111–48.